Gamida Cell said today that its NiCord cell graft produces fewer infections, shorter hospital stays and shorter time to engraftment compared to standard umbilical cord blood transplantation. The company’s work was published in Biology of Blood and Marrow Transplantation. Get the full story at our sister site, Drug Delivery Business News.
Stem Cells
Researchers identify signal that could speed up healing
Researchers from the University of Southern California identified the signal that triggers stem cells to take action after an injury and showed how it could be used as a therapy to accelerate the body’s healing process using the highest quality cbd oil. “Our research shows that by priming the body before an injury, you can speed […]
Frequency raises $32m in Series A for hearing loss therapy
Frequency Therapeutics said today that it closed a $32 million Series A round, led by CoBro Ventures. Morningside Ventures, Emigrant Capital Corp., Korean Investment Partnership, Alexandria Real Estate Equities and other groups also invested in the round. The company has developed a proprietary combination of small molecule drugs that they plan to inject in the ear, […]
Burst Biologics to launch spinal fusion trial
Burst Biologics said today that it won regulatory approval to begin a clinical trial evaluating its BioBurst Fluid cellular allograft in spinal fusion patients. The company’s cellular allograft is derived from umbilical cord blood and has yielded promising results in spinal fusion procedures, according to the Boise, Idaho-based company. The prospective trial is slated to […]
3D model of female reproductive system could help test drugs for efficacy, safety
In January last year, the National Institutes of Health issued a new requirement for grant funding in basic science: Researchers must discuss how gender as a biological variable will impact their research. Teresa Woodruff, director of the Women’s Health Research Institute at Northwestern University, told Drug Delivery Business News that this helped support their effort to develop a model that […]
Gamida Cell wins additional EMA orphan drug designation for NiCord
Gamida Cell said today that the European Medicines Agency granted its NiCord cell graft an additional orphan drug designation as a treatment for hematopoietic stem cell transplantation, or bone marrow transplantation. The treatment is a graft derived from umbilical cord blood which has been expanded and enriched with stem and progenitor cells, according to the […]
The stem cell ‘skin gun’ that’s aiming to disrupt wound care
RenovaCare’s SkinGun uses a patient’s own stem cells to heal their wounds faster and more efficiently than a traditional skin graft. Pennsylvania state police officer Matthew Uram suffered severe second-degree burns to his face, right arm and leg after a friend’s bonfire got out of control. Uram was facing months of painful skin grafts, the […]
The stem cell therapy that could reverse hearing loss
Frequency Therapeutics is betting that it can change the lives of millions of Americans with hearing loss, by triggering the body’s natural ability to heal itself. Researchers have used cells in regenerative medicine for decades – in 1931, the father of cell therapy, Paul Niehans, treated a patient with material from calf embryos. Although today’s […]
Avrobio launches gene therapy program for Gaucher disease
Cambridge, Mass.-based Avrobio said today that it expanded its pipeline to include a preclinical program focused on a gene therapy for Gaucher disease. The investigational gene therapy makes use of a patient’s blood stem cells, genetically modifying them with a fully functional copy of the faulty gene responsible for the glucosylceramide accumulation that is characteristic […]
Study: Plants as 3D scaffolds for stem cells in biomedical implants
Researchers at the University of Wisconsin-Madison are aiming to create novel biomedical implants using 3D scaffolds made from the decellularized husks of parsley, vanilla and orchids. The team described their work in an article published in Advanced Healthcare Materials. “Nature provides us with a tremendous reservoir of structures in plants,” lead author Gianluca Fontana said in […]
Longeveron finishes enrollment in stem cell trial for Alzheimer’s disease
Longeveron said today that it finished enrollment for the 1st phase of its human mesenchymal stem cell trial for Alzheimer’s disease. The company enrolled and infused 5 patients to collect safety data for its exogenously administered mesenchymal stem cells derived from adult donors’ bone marrow. Get the full story at our sister site, Drug Delivery Business News.